Clinical trials of mediator-directed therapy in sepsis: What have we learned?

Intensive Care Medicine, Supplement

Volumn 26, Issue 1, 2000, Pages

  Marshall, J C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOTHERAPY; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ANTIBODIES, MONOCLONAL; ENDOTOXEMIA; HUMANS; IMMUNOTHERAPY; INTENSIVE CARE; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; SEPSIS;

EID: 0034069259     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Rogers DE (1959) The changing pattern of life-threatening microbial disease. N Engl J Med 261: 677-683
2. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE (1980) The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 141: 55-63
3. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664
4. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC (1990) Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336-340
5. Bone RC (1992) Phospholipids and their inhibitors: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 20: 884-890
6. Lorente JA, Landin L, De Pablo R, Renes E, Liste D (1993) L-arginine pathway in the sepsis syndrome. Crit Care Med 21: 1287-1295
7. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101: 816-823
8. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI (1982) Treatment of gramnegative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307: 1225-1230
9. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324: 429-436
10. Fisher CJ, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBreque JF, Catalano MA, Knaus WA, Sadoff JC (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 271: 1836-1843
11. Fisher CJ, Jr., Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334: 1697-1702
12. Grover R, Lopez A, Lorente J, Steingrub J, Bakker J, Willatts S, McLuckie A, Takkala J (1999) Multicenter, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 27:A33
13. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1100
14. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RMH, Panacek EA, Vincent JL, Foulke GE, Warren EL, Garrard C, Park G, Bodmer MW, Cohen J, Van der Linden CJ, Cross AS, Sadoff JC (1993) Influence of an antitumor necrosis factor monoclonal antibody on cytokine level in patients with sepsis. Crit Care Med 21: 318-327
15. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M (1995) CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23: 1461-1469
16. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta R, Monk DN, Shenkin A, Hill GL (1998) Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis a randomized clinical trial. Crit Care Med 26: 1650-1659
17. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J (1996) Assessment of the safety and efficacy of the monnoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733-742
18. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273: 934-941
19. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24: 1431-1440
20. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 351: 929-933
21. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 277: 1531-1538
22. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22: 12-21
23. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBreque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115-1124
24. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 654-658
25. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389-393
26. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ (1992) ACCP/ SCCM CONSENSUS CONFERENCE. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655
27. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 273: 117-123
28. Muckart DJJ, Bhagwanjee S (1997) The ACCP/SCCM consensus conference definitions of the systemic inflammatory response syndrome (SIRS) and allied disorders in relation to critically injured patients. Crit Care Med 25: 1789-1795
29. Vincent JL (1997) Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 25: 372-374
30. Damas P, Canivet JL, De Groote D, Vrindts Y, Albert A, Franchimont P, Lamy M (1997) Sepsis and serum cytokine concentrations. Crit Care Med 25: 405-412
31. Wortel CH, von der Mohlen MA, van Deventer SJ, Sprung CL, Jastremski M, Lubbers MJ, Smith CR, Allen IE, Ten Cate JW (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 168: 1367-1374
32. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial. Ann Intern Med 121: 1-5
33. The National Committee for the Evaluation of Centoxin (1994) The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med 154: 2484-2491
34. Casey LC, Balk RA, Bone RC (1993) Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771-778
35. Marshall JC, Creery D (1998) Pre-clinical models of sepsis. Sepsis 2: 187-197
36. Panacek EA, Kaul M (1999) IL-6 as a marker of excessive TNF-a activity in sepsis. Sepsis 3: 65-73
37. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Carrdiac Arrhythmia Suppression Trial. N Engl J Med 324: 781-788
38. Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477
39. CDC (1989) Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. MMWR 39: 31-34
40. Hebert PC (1997) Mortality as an outcome in sepsis trials. Sepsis 1: 35-40
41. Lau J, Antman EM, Jimenez-Silva J (1992) Cumulative meta-analyses of therapeutic trials for myocardial infarction. N Engl J Med 327: 248
42. Prendergast TJ, Claessens MT, Luce JM (1998) A national survey of end-of-life care for critically ill patients. Am J Respir Crit Care Med 158: 1163-1167
43. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23: 1638-1652
44. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart K, Suter P, Thijs LG (1996) The sepsis-related organ failure assessment (SOFA) score to describe organ dysfunction/failure. Intens Care Med 22: 707-710
45. Schwieterman W, Roberts R (1997) FDA perspective on study design for therapies for severe sepsis. Sepsis 1: 69
46. Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 24: 1441-1447
47. Petrie D, Lane P, Stewart TC (1996) A evaluation of patient outcomes comparing trauma team activated versus trauma team not activated using TRISS analysis. J Trauma 41: 870-875
48. Gordon TA, Bowman HM, Tielsch JM, Bass EB, Burleyson GP, Cameron JL (1998) Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg 228: 71-78
49. Cebul RD, Snow RJ, Pine R, Hertzer NR, Norris DG (1998) Indications, outcomes, and provider volumes for carotid endarterectomy. JAMA 279: 1282-1287
50. Ronning OM, Guldvog B (1999) Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial. Stroke 29: 58-62